Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
October 13, 2017

Huge drug development opportunities in global immuno-oncology area in Asia-Pacific

The global immuno-oncology arena, estimated to be valued more than $33bn, provides a number of opportunities for drug development companies in the Asia Pacific (APAC) region, according to GlobalData’s R&D Visualization Bullseye Chart.

The global immuno-oncology arena, estimated to be valued more than $33bn, provides a number of opportunities for drug development companies in the Asia Pacific (APAC) region, according to GlobalData’s R&D Visualization Bullseye Chart.

The chart for PD-(L)1 combination pipeline shows that APAC companies only contribute to the development of a minority of PD-(L)1 combinations.

The chart indicates that of all PD-(L)1 combinations, companies from the region are involved in just 6.4% of the investigations. Japan is the leading developer of PD-(L)1 combinations in the region with Takeda and Eisai being the biggest contributors.

“The chart indicates that of all PD-(L)1 combinations, companies from the region are involved in just 6.4% of the investigations.”

China is set to outperform in the future, with three out of 15 anti-PD-(L)1 molecules currently being investigated as both monotherapy and combination, says Fenix Leung GlobalData Healthcare Consultant.

BeiGene, Shanghai Junshi, and Jiangsu Hengrui are the biggest Chinese companies  developing PD-(L)1 combinations.

The R&D chart also indicates that PD-(L)1 combinations are being studied in solid tumour (multiple tumour types) fields, a strategy being adopted by companies to target several tumour types.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU